Napredna pretraga

Pregled bibliografske jedinice broj: 738881

CSF tau proteins in evaluation of patients with suspected dementia


Boban, Marina; Grbić, Kristina; Hof, Patrick R; Hamann, Christine; Ackl, Nibal; Mimica, Ninoslav; Bader, Benedikt; Danek, Adrian; Šimić, Goran
CSF tau proteins in evaluation of patients with suspected dementia // Clinical Neuropathology Vol 25 (6) - Abstracts of the 37th Professor Janez Plečnik Memorial Meeting: Recent Progress in Dementia Research / Weis, J (ur.).
Deisenhofen-Munich: Dustri-Verlag Dr. Karl Feistle GmbH & Co. KG, 2006. str. 306-306 (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
CSF tau proteins in evaluation of patients with suspected dementia

Autori
Boban, Marina ; Grbić, Kristina ; Hof, Patrick R ; Hamann, Christine ; Ackl, Nibal ; Mimica, Ninoslav ; Bader, Benedikt ; Danek, Adrian ; Šimić, Goran

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Clinical Neuropathology Vol 25 (6) - Abstracts of the 37th Professor Janez Plečnik Memorial Meeting: Recent Progress in Dementia Research / Weis, J - Deisenhofen-Munich : Dustri-Verlag Dr. Karl Feistle GmbH & Co. KG, 2006, 306-306

Skup
37th Professor Janez Plečnik Memorial Meeting: Recent Progress in Dementia Research

Mjesto i datum
Ljubljana, Slovenija, 07-08.12.2006.

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
CSF; Tau proteins; Dementia suspected patients; AD

Sažetak
The cerebrospinal fluid (CSF) levels of phosphorylated tau proteins reflect the phosphorylation state of tau in the brain. Using monoclonal an-tibodies, different tau phospho-epi-topes can be sensitively detected in CSF of dementia-suspected patients. Our objective was to determine the di-agnostic value of CSF total tau protein (t-tau) and tau protein phos-phorylated at threonine 181 and 199 (p-taul81 and p-taul99) in early-on-set Alzheimer's disease (AD) versus healthy controls (HC) and other primaj causes of dementia, such as frontotemporal dementia (FTD), vas-cular dementia (VaD) and diffuse Lewy-body disease (DLBD). The study included patients with a clinical diagnosis of suspected dementia, probable and possible AD (n = 11), as well as FTD (n = 5), VaD (n = 8), DLBD (n = 2) and HC (n - 12). CSF levels were measured using commer-cially available ELISA kits (t-tau and p-taul99 - BioSource, Camarillo, CA, USA and p- taul81 - Innogenet-ics, Ghent, Belgium). Mean CSF t-tau and CSFp-tau 181 levels were signifi-cantly elevated in AD patients com-pared to FTD, VaD and HC. In differ-entiating between AD versus FTD and VaD, CSF p-tau!81 showed best sensitivity and specificity (AD vs DLB: sens. 91%, spec. 94% ; AD vs VaD: sens. 91%, spec. 95%). P-taul99 showed much lower specificity. Total tau and p-tau 181 are useful biological markers for distinguishing AD from other primary causes of dementia, such as FTD and VaD. The time has come to include CSF examination of tau proteins as part of the routine di-agnostic workup for patients with suspected dementia in both clinical and neuropathological evaluation of a patient.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Medicinski fakultet, Zagreb,
Klinika za psihijatriju Vrapče,
Klinički bolnički centar Zagreb